Kidney Cancer

NASHVILLE, Tenn. — Pavlos Msaouel, MD, PhD, received the Kidney Cancer Association’s Christopher G. Wood Rising Star Award.

NASHVILLE, Tenn. — Nizar M. Tannir, MD, FACP, received the Nicholas J. Vogelzang Humanitarian Award from the Kidney Cancer Association.

MADRID — Treatment with toripalimab plus axitinib resulted in significantly longer PFS than treatment with sunitinib in patients with previously untreated advanced kidney cancer, according to a presentation from ESMO Congress.

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.

MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.

A subcutaneous nivolumab formulation showed noninferior pharmacokinetics and objective response rates compared with IV nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma, according to the agent’s manufacturer.

Stereotactic ablative body radiotherapy conferred 100% disease control and cancer-specific survival over a 3-year follow-up period among older adults with inoperable kidney cancer, results from a phase 2 study showed.

“This specialty is not just about kidney cancer; it is about any cancer and cancer-related treatment and its effect on the kidney,” Kenar Dinesh Jhaveri, MD, said about the emerging area of onconephrology.

Adolescent and young adult survivors of kidney cancer appeared at significantly increased risk for left ventricular ejection fraction, according to study results published in Journal of the National Comprehensive Cancer Network.

CHICAGO —Age-adjusted mortality rates in kidney cancer have decreased across all genders, races and ethnicities and in most states in the U.S. over the past 2 decades,according to a poster presentation at ASCO Annual Meeting.